United States: FDA Approval Pathway and Prescribing Rules for GLP-1 Drugs
How GLP-1 medications move through FDA approval, what prescription-only status means in practice, and where telehealth prescribing fits in.
By the GLP Semaglutide editorial team · Last updated May 20, 2026
In the United States, GLP-1 receptor agonists are prescription-only medications regulated by the FDA. Manufacturers must demonstrate safety and efficacy for each specific indication (e.g., type 2 diabetes vs. chronic weight management) before that use is added to a drug's approved label.
Off-label prescribing
Physicians may legally prescribe an FDA-approved drug off-label — for example, prescribing Ozempic for weight loss even though its approved label is for type 2 diabetes — based on clinical judgment. Off-label use is legal but is not the same as an FDA-reviewed indication, and insurance coverage for off-label use is inconsistent.
Telehealth prescribing
Telehealth platforms have become a major channel for GLP-1 prescriptions, operating under state-by-state telemedicine rules that generally require a licensed clinician to conduct an evaluation before prescribing. Requirements around synchronous (live video) versus asynchronous (questionnaire-based) evaluation vary by state and have been an active area of regulatory attention.
Where to verify
For current, authoritative information, consult the FDA's drug database (accessdata.fda.gov), your state medical board's telehealth rules, and your insurance plan's formulary documents directly.
Primary sources